<img alt="" height="1" width="1" />
Novartis drug helps rare tumors, filing this year
MILAN (Reuters) - Patients with advanced neuroendocrine tumors, a rare type of cancer, lived 5.1 months longer without their disease worsening when given Novartis&#39;s drug Afinitor, researchers said on Monday. ...
Novartis&#39;s Afinitor Fails to Slow Rare Form of Pancreatic Cancer in TrialBloomberg
Novartis To File Afinitor After Phase III Study DataWall Street Journal
Novartis International AG: Phase III Novartis data show potential benefit of ...Reuters (press release)
Frontier India - News, Analysis, Opinion
all 34 news articles &raquo;